PHILADELPHIA, July 9, 2024 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific gene medicines, today announced that…
Press Release
Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
July 09, 2024
Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic
June 21, 2023
PHILADELPHIA, June 21, 2023 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, today announced…
Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies
May 09, 2023
PHILADELPHIA, May 9, 2023 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for…
Interius BioTherapeutics Hosts Immersive, Hands-on Event to Ignite Students’ Passion for Science
April 27, 2023
Philadelphia, PA – April 27, 2023 – Interius BioTherapeutics, a preclinical stage gene therapy company…
Interius Bio Announces Granting of US Patent to Support in Vivo Cell-Specific Gene Delivery Platform
December 09, 2021
Company also celebrates “Deal of the Year” awarded by The Penn Center for Innovation PHILADELPHIA,…
Pennovation Lab Welcomes New Tenant Interius BioTherapeutics to Its Innovation Ecosystem
October 05, 2021
Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform
May 18, 2021
Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing.